Business Context and Reporting Period
This Form 8-K Current Report from Revolution Medicines, Inc. (RVMD) covers events occurring on June 18, 2026. The filing primarily addresses significant corporate governance changes, including the announced retirement of a key executive and the results of the Company's Annual Meeting of Stockholders.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain financial performance data. Consequently, there are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Corporate Events
Executive Departure and Transition
- Steve Kelsey, M.D., President of Research and Development, announced his intent to retire effective January 4, 2027.
- Effective July 1, 2026, Dr. Kelsey will transition to the role of Senior Advisor to the Chief Executive Officer.
- Upon retirement, Dr. Kelsey will be eligible for certain equity award benefits under the Company's retirement policy.
- The Company contemplates appointing Dr. Kelsey to the Board of Directors effective January 4, 2027, subject to Board approval.
Annual Meeting Results
On June 18, 2026, stockholders voted on three proposals. As of the record date (April 23, 2026), 212,592,561 shares were outstanding and entitled to vote.
| Proposal | Outcome | Key Vote Counts |
|---|---|---|
| Proposal 1: Election of Class III Directors | Approved | Alexis Borisy: 127,181,172 For / 33,660,532 Withheld Mark A. Goldsmith: 157,681,628 For / 3,160,076 Withheld |
| Proposal 2: Ratification of PricewaterhouseCoopers LLP as Auditor | Approved | 181,309,783 For / 206,306 Against / 139,256 Abstentions |
| Proposal 3: Advisory Vote on Executive Compensation | Approved | 155,110,825 For / 5,554,146 Against / 176,733 Abstentions |
Guidance, Outlook, and Risks
The filing includes forward-looking statements regarding Dr. Kelsey's retirement timeline, his transition to a senior advisor role, and his potential Board appointment. Management notes that these events are subject to risks and uncertainties, including:
- The possibility that the retirement or transition may not occur on the anticipated timeline or terms.
- The Board appointment remains subject to approval and may not occur.
- Risks related to the Company's ability to attract, retain, and transition key personnel.
Investors are directed to the "Risk Factors" section of the Company's Form 10-Q filed on May 6, 2026, for a comprehensive list of business risks.
Investor Verification Checklist
- Verify the final appointment of Dr. Steve Kelsey to the Board of Directors, as it is currently contemplated but subject to approval.
- Monitor the transition plan for the President of Research and Development role following Dr. Kelsey's retirement in January 2027.
- Review the definitive Proxy Statement (Schedule 14A) filed on April 27, 2026, for detailed background on the director nominees and executive compensation.
- Confirm the Company's ability to retain key scientific and operational talent during the leadership transition period.